CLECELL Co., Ltd. is a manufacturer specializing in 3D bioprinting technology for the creation of artificial human tissues and organoids. Their bioprinting platform focuses on high-resolution, high-throughput manufacturing, enabling the development of realistic in vitro skin models and patient-specific 3D cancer tissues. This innovative approach aims to eliminate the need for animal testing and facilitates rapid testing of chemotherapeutic agents. CLECELL is actively involved in advancing the fields of tissue engineering and regenerative medicine through collaborations with research institutes, biotechnology firms, and healthcare providers.

The company specializes in manufacturing advanced bioprinting technologies aimed at producing realistic 3D human tissues. We provide high-quality bioinks and cutting-edge bioprinting solutions specifically designed for life sciences research laboratories. Our innovative formulations enable human cells to grow and proliferate in environments that closely mimic the human body, facilitating the transition from 2D to 3D culture systems. By focusing on the development of novel materials, we enhance product performance to meet the unique requirements of diverse applications in tissue engineering and regenerative medicine.

The company specializes in advanced bioprinting technologies and regenerative medicine solutions, offering a hyper-personalized organ regeneration platform. It focuses on the development of biomaterials for applications such as skin and cartilage regeneration, utilizing 3D bioprinting and tissue engineering techniques. The product range includes heart patches, ECM (extracellular matrix) components, and bioinks designed for use in healthcare settings, particularly in hospitals. The company operates as a manufacturer in the biotechnology sector, with capabilities in retinal and kidney regeneration as well as anti-aging solutions.

The company is a manufacturer and service provider specializing in biotechnology and tissue engineering. It offers products such as ECM scaffolds and provides services to researchers focused on 3D cell culture. Through these technologies, the company aims to advance the production of artificial organs.

Brinter is a BioTech/MedTech company specializing in the development of 3D bioprinted implants for regenerative medicine. The company manufactures patented 3D bioprinters and biomaterials, focusing on cartilaginous applications such as meniscus, nose, ear, hip socket, and faceted joint cartilage. Brinter licenses these innovative clinical applications to clinics, hospitals, and ambulatory surgical centers for use in reconstructive and cosmetic surgery, advocating for health equality and ethical advances in the field.

Axolotl Biosystems is a manufacturer specializing in high-resolution desktop 3D bioprinters and bioinks designed for tissue engineering and regenerative medicine. The company offers powerful, fast, and reliable bioprinting platforms tailored to meet the specific needs of researchers. Their products aim to reduce the costs associated with traditional 3D bioprinting systems while providing flexible open system architecture for construct design. Axolotl Biosystems focuses on creating functional three-dimensional living tissues using advanced technologies such as Melt Electro Writing, Electrospinning, and bioink formulations, including GelMA.